1 |
Hattori, Y., H. Kakishita, K. Akimoto, M. Matsumura, and K. Kasai. 2001. Glycated serum albumin-induced vascular smooth muscle cell proliferation through activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by protein kinase C. Biochem. Biophys. Res. Commun. 281, 891-896.
DOI
|
2 |
Hattori, Y., M. Suzuki, S. Hattori, and K. Kasai. 2002. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 39, 22-28.
DOI
|
3 |
Akira, S. and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511.
DOI
|
4 |
Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
DOI
|
5 |
Zernecke, A., E. Shagdarsuren, and C. Weber. 2008. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28, 1897-1908.
DOI
|
6 |
Yang, X., D. Coriolan, V. Murthy, K. Schultz, D. T. Golenbock, and D. Beasley. 2005. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am. J. Physiol. Heart Circ. Physiol. 289, H1069-1076.
DOI
|
7 |
Yang, X., D. Coriolan, K. Schultz, D. T. Golenbock, and D. Beasley. 2005b. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 25, 2308-2314.
DOI
|
8 |
Yang, X., V. Murthy, K. Schultz, J. B. Tatro, K. A. Fitzgerald, and D. Beasley. 2006. Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 291, H2334-2343.
DOI
|
9 |
Zuany-Amorim, C., J. Hastewell, and C. Walker. 2002. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discov. 1, 797-807.
DOI
|
10 |
Michelsen, K. S., M. H. Wong, P. K. Shah, W. Zhang, J. Yano, T. M. Doherty, S. Akira, T. B. Rajavashisth, and M. Arditi. 2004. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 101, 10679-10684.
DOI
|
11 |
Ross, R. 1986. The pathogenesis of atherosclerosis-an update. N. Engl. J. Med. 314, 488-500.
DOI
|
12 |
Salazar, R., R. Brandt, and S. Krantz. 1995. Expression of fructosyllysine receptors on human monocytes and monocyte- like cell lines. Biochim. Biophys. Acta. 1266, 57-63.
DOI
|
13 |
Singh, R., A. Barden, T. Mori, and L. Beilin. 2001. Advanced glycation end-products: a review. Diabetologia 44, 129-146.
DOI
|
14 |
Sun, H. N., S. U. Kim, M. S. Lee, S. K. Kim, J. M. Kim, M. Yim, D. Y. Yu, and D. S. Lee. 2008. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent activation of phosphoinositide 3-kinase and p38 mitogenactivated protein kinase signal pathways is required for lipopolysaccharide-induced microglial phagocytosis. Biol. Pharm. Bull. 31, 1711-1715.
DOI
|
15 |
Herder, C., B. Haastert, S. Muller-Scholze, W. Koenig, B. Thorand, R. Holle, H. E. Wichmann, W. A. Scherbaum, S. Martin, and H. Kolb. 2005. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54, S11-17.
DOI
|
16 |
Wu, V. Y. and M. P. Cohen. 1995. Evidence for a ligand receptor system mediating the biologic effects of glycated albumin in glomerular mesangial cells. Biochem. Biophys. Res. Commun. 207, 521-528.
DOI
|
17 |
Wu, V. Y., C. W. Shearman, and M. P. Cohen. 2001. Identification of calnexin as a binding protein for Amadori-modified glycated albumin. Biochem. Biophys. Res. Commun. 284, 602-606.
DOI
|
18 |
Wu, Y. M., D. R. Robinson, and H. J. Kung. 2004. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res. 64, 7311-7320.
DOI
|
19 |
Higai, K., A. Shimamura, and K. Matsumoto. 2006. Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin. Chim. Acta. 367, 137-143.
DOI
|
20 |
Higgins, P. J. and H. F. Bunn. 1981. Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J. Biol. Chem. 256, 5204-5208.
|
21 |
Hollestelle, S. C., M. R. De Vries, J. K. Van Keulen, A. H. Schoneveld, A. Vink, C. F. Strijder, B. J. Van Middelaar, G. Pasterkamp, P. H. Quax, and D. P. De Kleijn. 2004. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109, 393-398.
DOI
|
22 |
Kawai, T. and S. Akira. 2005. Toll-like receptor downstream signaling. Arthritis Res. Ther. 7, 12-19.
DOI
|
23 |
Libby, P. 2002. Inflammation in atherosclerosis. Nature 420, 868-874.
DOI
|
24 |
Bunn, H. F., K. H. Gabbay, and P. M. Gallop. 1978. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200, 21-27.
DOI
|
25 |
Libby, P., P. M. Ridker, and A. Maseri. 2002. Inflammation and atherosclerosis. Circulation 105, 1135-1143.
DOI
|
26 |
Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K. Fukasawa, G. F. Vande Woude, and N. G. Ahn. 1994. Transformation of mammalian cells by constitutively active MAP kinase. Science 265, 966-970.
DOI
|
27 |
Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145.
DOI
|
28 |
Clements, R. S., Jr., W. G. Robison, Jr., and M. P. Cohen. 1998. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J. Diabetes Complications 12, 28-33.
DOI
|
29 |
Cohen, M. P., R. S. Clements, J. A. Cohen, and C. W. Shearman. 1996. Glycated albumin promotes a generalized vasculopathy in the db/db mouse. Biochem. Biophys. Res. Commun. 218, 72-75.
DOI
|
30 |
Derijard, B., J. Raingeaud, T. Barrett, I. H. Wu, J. Han, R. J. Ulevitch, and R. J. Davis. 1995. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267, 682-685.
DOI
ScienceOn
|
31 |
Edfeldt, K., J. Swedenborg, G. K. Hansson, and Z. Q. Yan. 2002. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161.
|
32 |
Eickelberg, O., M. Roth, R. Mussmann, J. J. Rudiger, M. Tamm, A. P. Perruchoud, and L. H. Block. 1999. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 99, 2276-2282.
DOI
ScienceOn
|